Financial burden of cancer survivorship varies by age, cancer site

Key points
- Survivors of cancer pay thousands of dollars in excess medical expenditures every year, with the excess financial burden varying by age and cancer site, according to a new American Cancer Society study.
- As a group, cancer survivors (estimated to number 14.5 million in the United States in 2014) face greater economic burden, including medical expenditures and productivity losses.
- Researchers led by Zhiyuan 'Jason' Zheng, PhD, senior health services researcher in the Surveillance and Health Services Research program at the American Cancer Society, used 2008 to 2012 Medical Expenditure Panel Survey data to measure excess economic burden attributable to the three most prevalent cancers.
- They found cancer survivors experienced annual excess medical expenditures compared with individuals without a cancer history.
Survivors of cancer pay thousands of dollars in excess medical expenditures every year, with the excess financial burden varying by age and cancer site, according to a new American Cancer Society study. The study, appearing early online in the Journal of the National Cancer Institute, says targeted efforts will be important to reduce the economic burden of cancer.
As a group, cancer survivors (estimated to number 14.5 million in the United States in 2014) face greater economic burden, including medical expenditures and productivity losses. But relatively little is known about whether that burden varies by cancer site compared to similar individuals without a cancer history.
Researchers led by Zhiyuan 'Jason' Zheng, PhD, senior health services researcher in the Surveillance and Health Services Research program at the American Cancer Society, used 2008 to 2012 Medical Expenditure Panel Survey data to measure excess economic burden attributable to the three most prevalent cancers. They calculated excess annual medical expenditures and productivity losses (employment disability, missed work days, and days stayed in bed) for colorectal (n = 540), female breast (n = 1568), and prostate (n = 1170) cancer survivors, and for those without a cancer history (n = 109,423). They stratified the data by cancer site and age (nonelderly: 18-64 years vs elderly: ?65 years), and controlled for age, sex, race/ethnicity, marital status, education, number of comorbidities, and geographic region.
They found cancer survivors experienced annual excess medical expenditures compared with individuals without a cancer history. For the nonelderly population, annual excess expenditures were $8657 for colorectal cancer; $5119 for breast cancer; and $3586 for prostate cancer. For the elderly population, annual excess expenditures were: colorectal: $4913; breast: $2288; prostate: $3524.
Nonelderly colorectal and breast cancer survivors were more likely to have employment disability as well as productivity loss at work (7.2 days) and at home (4.5 days). In contrast, elderly survivors of all three cancer sites had comparable productivity losses as those without a cancer history.
"This study helps us quantify the excess economic burden associated with the three major cancer sites," said Dr. Zheng. "Understanding this burden is an important step to shape health care policies to target areas where cancer survivors are most vulnerable."
###
Article: Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States JNCI J Natl Cancer Inst (2016) 108 (5): djv382 doi: 10.1093/jnci/djv382
###
David Sampson
[email protected]
American Cancer Society
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsBreast cancer risk varies significantly among BRCA1 and BRCA2 carriers
There is a broad variation in the risk of developing breast cancer among people who carry the BRCA1 and BRCA2 gene mutation, according to a study in the January 9/16 issue of JAMA. BRCA1 and BRCA2 are gene mutations…
10 January 2008
NewsProstate cancer cost varies widely by treatment
The total cost burden of prostate cancer varies significantly by treatment type, according to a new report. "I would like this information to be used by clinicians to emphasize that, especially, the initial costs of a…
11 January 2007
NewsRemoval of Ovaries Decreases Cancer Risk for Women at High-Risk
Women with mutations in the BRCA1 or BRCA2 genes can significantly reduce their risk of certain types of cancer by having their ovaries removed, according to a study in the July 12 issue of JAMA. Women with a harmful…
13 July 2006







